Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...

AAD 2025 IL-23 Inhibitors Tested for Expanded Role in Psoriasis In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions ...

Expert Rev Gastroenterol Hepatol. 2012;6(1):43-55. Improving Gluten Strength Gluten is important to the baking industry because it provides elasticity and shape to dough by forming a network of ...

Mar. 13, 2025 — Older adults who were exposed to seasonal flu viruses that circulated prior to 1968 are more likely to have some protection against H5N1, and children would benefit more from ...